Does Quartz Cover GLP-1? Formularies, Appeals, and Alternatives

Whether Quartz covers a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound depends on three things: which Quartz plan you have, why the drug was prescribed, and whether the plan’s utilization rules (prior authorization, step therapy, quantity limits) are satisfied. In broad strokes, Quartz is far more likely to cover a GLP-1 prescribed for type 2 diabetes than one prescribed for weight loss, and Medicare Advantage members face a separate federal rule that currently blocks Part D coverage for obesity until a new CMS bridge program opens on July 1, 2026.

Diabetes Versus Weight Loss Is the Deciding Factor

The same molecule can be covered or excluded depending on the brand and the indication. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for chronic weight management, with Wegovy also carrying a cardiovascular risk reduction indication and Zepbound carrying an indication for obstructive sleep apnea.

Quartz’s prior authorization criteria library for its Small Group and Individual plans lists “Diabetic GLP-1 Agonists” as a dedicated category.1Quartz Benefits. HIX-RX Criteria Library The category name points to a review pathway built around diabetes, not obesity. The 2025 Individual and Family Standard Formulary’s therapeutic index does not include an “Anti-obesity” or “Weight loss” category, and the formulary generally excludes cosmetic treatments and nutritional supplements.2Quartz Benefits. 2025 Individual and Family Standard 4-Tier Drug Formulary Taken together, that suggests GLP-1 coverage on Quartz’s commercial plans is oriented around FDA-approved medical indications like type 2 diabetes rather than weight management on its own.

If your provider prescribes a GLP-1 for diabetes, expect the drug to be on the formulary with prior authorization. If the prescription is for weight loss alone, expect the drug to be excluded or subject to a coverage-exception process that requires documented medical necessity.

How Quartz Builds Its Drug Coverage

Quartz manages its formularies in partnership with OptumRx. Drugs sit on tiers running from zero-dollar generics up through Preferred Brand, Non-Preferred, and Specialty, with higher tiers carrying higher cost-sharing.3Quartz Benefits. 2026 Quartz Individual and Family Non-Standard ACA Drug Formulary GLP-1s, when covered, typically land on higher tiers.

On top of tier placement, Quartz uses the three standard utilization management tools: prior authorization, step therapy (try a lower-cost alternative first), and quantity limits (a cap per fill).4Quartz Benefits. Pharmacy Benefits – Individual and Family 2026 GLP-1s commonly trigger all three. Tier placements can change quarterly, so the formulary that applied last year is not necessarily the formulary that applies now.

Medicare Advantage Members: A Separate Set of Rules

Quartz offers Medicare Advantage plans in Wisconsin and Iowa. Under current Medicare law, Part D plans cannot cover drugs prescribed solely for weight loss, so Quartz Medicare Advantage members cannot obtain Wegovy or Zepbound for obesity through their Part D benefit regardless of what the formulary lists. GLP-1s prescribed for covered indications such as type 2 diabetes or cardiovascular risk reduction follow the standard Part D formulary process.5KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid

That changes partially on July 1, 2026, when the CMS Medicare GLP-1 Bridge program begins covering Wegovy and Zepbound for obesity for eligible Medicare beneficiaries. The bridge operates outside the normal Part D benefit, so Quartz does not need to opt in for its Medicare Advantage members to use it. Eligible beneficiaries who meet BMI and clinical criteria pay a flat $50 monthly copay, and claims run through a central system operated by Humana using a dedicated BIN/PCN. The $50 copay does not count toward Part D true out-of-pocket costs.6CMS.gov. Medicare GLP-1 Bridge

The bridge runs only through December 31, 2026. On January 1, 2027, CMS plans to launch the BALANCE Model, a longer-term voluntary program for Part D sponsors. Under BALANCE, the monthly copay would be $125 on basic Part D plans and $50 on enhanced or employer-group plans, with manufacturers supplying the drugs at a negotiated $245 per 30-day supply. Medicare Advantage plans would need to apply; CMS has said application details are coming in March 2026.7CMS.gov. BALANCE Model Quartz has not publicly indicated whether it will participate.

How to Confirm Coverage for Your Specific Plan

Because Quartz runs separate formularies for Medicare Advantage, individual/family, small group, and large group plans, there is no single yes-or-no answer. Check the formulary that actually applies to you:

  • Log in to Quartz MyChart at QuartzMyChart.com and open the Pharmacy Benefits section to view your formulary and run a drug price search.
  • Use the plan-specific online formulary search tools Quartz links to, powered by OptumRx and BenefitRx. You can look up a drug by name and see tier, restrictions, and estimated cost.4Quartz Benefits. Pharmacy Benefits – Individual and Family 2026
  • Download your plan’s printable formulary PDF and search for the drug name. Note the restriction codes: PA (prior authorization), ST (step therapy), and QL (quantity limits).2Quartz Benefits. 2025 Individual and Family Standard 4-Tier Drug Formulary
  • Call Quartz Member Services at (800) 496-7509 to confirm tier, prior authorization requirements, and cost-sharing for the specific GLP-1 you were prescribed.8Quartz Benefits. Pharmacy Benefits – Small Group 2026

Quartz’s own documentation notes that the formulary is a tool for understanding how a drug is covered and is not a guarantee of coverage. Your plan’s benefit rider and schedule of benefits ultimately control what gets paid.

What to Do if Quartz Denies Your GLP-1

Denials for GLP-1 medications are common across the industry, and the appeals process is built for this. Start with the denial letter and read it closely for the specific reason: missing documentation, unmet prior authorization criteria, or an unsatisfied step therapy requirement are the usual culprits. Resubmitting the same request without new information rarely changes the outcome.

Work with your prescribing provider to pull targeted documentation. That typically includes A1C and lipid labs, a detailed weight history, records of previous medications tried and why they were stopped, and the diagnosis codes that support medical necessity. A letter of medical necessity from your provider explaining why this specific drug fits your condition carries real weight.9U.S. News & World Report. Navigating Insurance Coverage for GLP-1 Medications

If the internal appeal fails, your provider can request a peer-to-peer review and speak directly with Quartz’s medical reviewer. Beyond that, members on fully insured plans can request an external review by an independent physician, usually decided within 30 to 45 days. Members on self-insured employer plans follow the appeals process set out in their plan documents under ERISA.10Obesity Action Coalition. Appealing a Denial

One practical angle: if a weight-loss prescription is denied, ask whether the drug could be covered under a different FDA-approved indication you also qualify for. Ozempic is approved for type 2 diabetes, Wegovy carries a cardiovascular risk reduction indication, and Zepbound is approved for obstructive sleep apnea. Reframing the prescription around a covered indication sometimes resolves the denial.

If Coverage Isn’t Available

When Quartz won’t cover the drug, manufacturer savings programs can lower the cost for members with commercial insurance. Novo Nordisk and Eli Lilly both offer savings cards that reduce monthly copays, though these programs are generally unavailable to anyone on Medicare, Medicaid, or other government-funded coverage. Patient assistance programs such as Lilly Cares and NovoCare provide the medication at little or no cost to people who meet income guidelines.

Compounded semaglutide and tirzepatide have been a lower-cost workaround, but the regulatory window is closing. The FDA removed tirzepatide from its drug shortages list in December 2024 and semaglutide in February 2025, ending the shortage exception compounders had relied on. The FDA’s enforcement discretion periods for state-licensed pharmacies and outsourcing facilities ended in spring 2025, and as of May 2026 the agency has proposed prohibiting outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide altogether, with public comment open through June 29, 2026.11FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize Compounded GLP-1s are unlikely to be covered by Quartz, and their availability going forward is uncertain.

For Quartz Medicare Advantage members, the July 2026 GLP-1 Bridge is the most accessible new pathway for obesity coverage, with a flat $50 monthly copay and no need for Quartz to opt in. Ask your provider about enrollment once the program opens.6CMS.gov. Medicare GLP-1 Bridge